Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.

Zhou D, Dejnirattisai W, Supasa P, Liu C, Mentzer AJ, Ginn HM, Zhao Y, Duyvesteyn HME, Tuekprakhon A, Nutalai R, Wang B, Paesen GC, Lopez-Camacho C, Slon-Campos J, Hallis B, Coombes N, Bewley K, Charlton S, Walter TS, Skelly D, Lumley SF, Dold C, Levin R, Dong T, Pollard AJ, Knight JC, Crook D, Lambe T, Clutterbuck E, Bibi S, Flaxman A, Bittaye M, Belij-Rammerstorfer S, Gilbert S, James W, Carroll MW, Klenerman P, Barnes E, Dunachie SJ, Fry EE, Mongkolsapaya J, Ren J, Stuart DI, Screaton GR. · 2021

Read Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. by Zhou D, Dejnirattisai W, Supasa P, Liu C, Mentzer AJ, Ginn HM, Zhao Y, Duyvesteyn HME, Tuekprakhon A, Nutalai R, Wang B, Paesen GC, Lopez-Camacho C, Slon-Campos J, Hallis B, Coombes N, Bewley K, Charlton S, Walter TS, Skelly D, Lumley SF, Dold C, Levin R, Dong T, Pollard AJ, Knight JC, Crook D, Lambe T, Clutterbuck E, Bibi S, Flaxman A, Bittaye M, Belij-Rammerstorfer S, Gilbert S, James W, Carroll MW, Klenerman P, Barnes E, Dunachie SJ, Fry EE, Mongkolsapaya J, Ren J, Stuart DI, Screaton GR. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7901269.txt.

Introduction

Zhou and co-authors report a laboratory study of the SARS-CoV-2 variant B.1.351 and immune escape. The variant was first seen in South Africa. It carries several changes in the spike protein, the part of the virus that antibodies target. The team tested how well blood from recovered patients and vaccine recipients could block it.

The changes let the variant grip the ACE2 receptor more tightly. They also helped it dodge many monoclonal antibodies. One change, E484K, drove much of that escape. Two other changes acted together against some antibody classes. In a number of cases, blood from past infection or vaccination gave only limited protection. The findings raised early concern about vaccine performance against new variants. They also showed which spike changes matter most.

Catalog record

CREATORZhou D, Dejnirattisai W, Supasa P, Liu C, Mentzer AJ, Ginn HM, Zhao Y, Duyvesteyn HME, Tuekprakhon A, Nutalai R, Wang B, Paesen GC, Lopez-Camacho C, Slon-Campos J, Hallis B, Coombes N, Bewley K, Charlton S, Walter TS, Skelly D, Lumley SF, Dold C, Levin R, Dong T, Pollard AJ, Knight JC, Crook D, Lambe T, Clutterbuck E, Bibi S, Flaxman A, Bittaye M, Belij-Rammerstorfer S, Gilbert S, James W, Carroll MW, Klenerman P, Barnes E, Dunachie SJ, Fry EE, Mongkolsapaya J, Ren J, Stuart DI, Screaton GR.
YEAR2021
COLLECTIONPAPERS
FORMATTXT
FILE SIZE67 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7901269

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera By Daming Zhou, Wanwisa Dejnirattisai, Piyada Supasa, Chang Liu, Alexander J. Mentzer, Helen M. Ginn, Yuguang Zhao, Helen M.E. Duyvesteyn, Aekkachai Tuekprakhon, Rungtiwa Nutalai, Beibei Wang, Guido C. Paesen Published in: Cell DOI: 10.1016/j.cell.2021.02.037 ABSTRACT Summary The race to produce vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began when the first sequence was published, and this forms the basis for vaccines currently deployed globally. Independent lineages of SARS-CoV-2 have recently been reported: UK, B.1.1.7; South Africa, B.1.351; and Brazil, P.1. These variants have multiple changes in the immunodominant spike protein that facilitates viral cell entry via the angiotensin-converting enzyme-2 (ACE2) receptor. Mutations in the receptor recognition site on the spike are of great concern for their potential for immune escape. Here, we describe a structure-function analysis of B.1.351 using a large cohort of convalescent and vaccinee serum samples. The receptor-binding domain mutations provide tighter ACE2 binding and widespread escape from monoclonal antibody neutralization largely driven by E484K, although K417N and N501Y act together against some important antibody classes. In a number of cases, it would appear that convalescent and some vaccine serum offers limited protection against this variant. INTRODUCTION Reports of a severe acute respiratory syndrome (SARS) emerged in December 2019, with rapidly increasing cases and deaths in Wuhan, China. The virus, SARS-coronavirus 2 (CoV-2) was rapidly identified, with the sequence published in January 2020 (Lu et al., 2020), and the disease it caused subsequently named coronavirus disease 2019 (COVID-19). SARS-CoV-2 has been estimated to have infected at least 118 million people, with 2.6 million deaths worldwide (https://www.worldometers.info/coronavirus). An unprecedented global scientific effort has been led by multiple pharmaceutical companies and academic laboratories to produce vaccines against SARS-CoV-2 (https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines), seen by many as the only realistic way to release populations from the harsh social isolation measures being implemented in many countries and the consequential severe economic disruption (Keogh-Brown et al., 2020). Many vaccine candidates have been developed, all aiming to generate antibody (and T cell) responses against the spike protein of SARS-CoV-2. These have been developed using spike sequences derived from the early Wuhan strain and include recombinant protein, inactivated virus, RNA, and virally vectored platforms (Krammer, 2020). With accelerated trials, the first efficacy results were delivered around 10 months following the first publication of the sequence of SARS-CoV-2 (Polack et al., 2020; Voysey et al., 2021a; Baden et al., 2021). Impressive results have now been reported from a variety of manufacturers: Novavax-recombinant spike and Janssen-adenoviral-vectored vaccines have recently reported good efficacy (https://www.novavax.com/sites/default/files/2021-02/20210202-NYAS-Novavax-Final.pdf; https://www.medscape.com/viewarticle/944933), while Moderna-RNA, Pfizer/BioNTech-RNA, and Oxford-AstraZeneca-chimp adenoviral-vectored vaccines have already received emergency use authorization (EUA) in a number of countries and will be deployed at massive scale in 2021. In the past few weeks, there have been reports of variant strains of SARS-CoV-2 emerging in different parts of the world. B.1.1.7 was first identified in the UK from a sample obtained in October 2020, B.1.351 was identified in October 2020 in South Africa, and P.1 was identified in Brazil in December 2020 (https://www.cogconsortium.uk/wp-content/uploads/2021/01/Report-2_COG-UK_SARS-CoV-2-Mutations.pdf). These variant strains have picked up multiple changes (deletions and substitutions) in the spike protein, 9 in B.1.1.7, 10 in B.1.351, and 12 in P.1, compared with the Wuhan sequence. Of greatest concern are mutations in the receptor-binding domain (RBD) of the spike protein. The RBD is contained in the S1 subunit of spike and is responsible for interacting with the SARS-CoV-2 cellular receptor angiotensin-converting enzyme-2 (ACE2) (Hoffmann et al., 2020). The ACE2 interaction surface of the RBD is a relatively small 25-amino-acid patch at the tip of the RBD (Shang et al., 2020), and because of its crucial role in viral attachment, it is also the site for binding of many potent neutralizing antibodies (Cerutti et al., 2021). Blocking RBD-ACE2 interaction is thought to play a major role in natural and vaccine-induced protection from SARS-CoV-2 infection. A number of such monoclonal antibodies (mAbs) have been combined into cocktails that are in advanced trials for treatment and prophylaxis of SARS-CoV-2 (Yang et al., 2020). The ACE2-binding surface is to some extent the Achilles heel of the virus as it can be blocked by some neutralizing antibodies; however, since it is so small, it also threatens immune escape, as small changes can throw off neutralizing antibodies, thereby reducing the ability of natural or vaccine-acquired immunity to contain viral replication. Selective pressure for changes in the ACE2 interaction surface can thus have two entirely separate drivers. First, as SARS-CoV-2 has recently crossed a zoonotic barrier, it may be expected that evolution of the ACE2 interaction surface may occur to increase affinity to ACE2 and thereby increase viral transmissibility. And second, conversely, changes to the ACE2 interaction surface may also reduce the protection afforded by previous infection or vaccination, potentially leading to escape from pre-existing immunity induced by natural infection or vaccines. All three recently identified variant SARS-CoV-2 strains have acquired mutations in the ACE2 interaction surface of the RBD: N501Y in B.1.1.7; K417N, E484K, and N501Y in B.1.351; and K417T, E484K, and N501Y in P.1. All three variants may lead to increased transmissibility, with good evidence for this with B.1.1.7 in the UK. These have rapidly expanded to become the dominant strains in the regions where they were first identified and global spread, particularly for B.1.1.7 and B.1.351, is causing considerable concern. Here, we examine neutralization of a B.1.351 viral isolate and compare this to neutralization of Victoria (SARS-CoV-2/human/AUS/VIC01/2020), an early Wuhan-related isolate. Neutralization assays are performed on a large panel of mAbs (Dejnirattisai et al., 2021), convalescent sera from early in the pandemic, sera from patients suffering from B.1.1.7, and finally sera from recipients of the Oxford-AstraZenca and Pfizer-BioNTech vaccines. There is evidence of widespread escape from mAbs, for which we provide a structural and biophysical description. Neutralization of B.1.351 by sera from naturally infected or vaccinated individuals is significantly reduced, leading in some cases to a complete inability to neutralize B.1.351 virus. RESULTS Mutational changes in B.1.351 A number of isolates of B.1.351 have been described, all of which have the key mutations K417N, E484K, and N501Y in the RBD. Tegally et al. (2021) reported an isolate containing 10 changes relative to the Wuhan sequence: L18F, D80A, D215G, L242-244 deleted, R246I, K417N, E484K, N501Y, D614G, and A701V. Sequencing of the strain used in this report, from a case in the UK, shows only 8 changes and lacks L18F and R246I compared with the Tegally et al. (2021) isolate. Coronavirus genome sequences were analyzed in both the UK, acquired from the COVID-19 Genomics UK (COG-UK) database (Tatusov et al., 2000), and South Africa, acquired from the Global Initiative on Sharing Avian Influenza Data (GISAID) (https://www.gisaid.org). It appears that B.1.1.7 and B.1.351 quickly became overwhelmingly dominant in the UK and South Africa, respectively. In the evolution of both the B.1.1.7 variant in the UK and the B.1.351 variant in South Africa, a substantial population of N-terminal domain (NTD)-deletion-only mutants (Δ69–70 in B.1.1.7 and Δ242–244 in B.1.153), and N501Y-only mutants were observed in both countries preceding the rising dominance of strains harboring both deletions and 501Y (Figures 1A and 1B). Counts of both “single-mutant” variants have since waned. The characteristic mutations for B.1.351

Read the complete text